Skip to main content
Premium Trial:

Request an Annual Quote

Affy Shares Surge 15 Percent Despite Predicted 11-Percent Drop in Q4 Revenue

NEW YORK (GenomeWeb News) — Affymetrix today said that fourth-quarter revenue will likely fall 11.5 percent year over year, but because the company beat analysts’ estimates its shares skyrocketed.
 
Affy today said it expects total revenues for the three months ended Dec. 31, 2006, to be around $100 million compared with $111.5 million during the same period in 2005. However, analysts expected the company to post $99.5 million for the period.
 
The news caused shares in Affy to surge 15.19 percent, or $3.30, to $25.02 in mid-afternoon trading. The stock remains down more than 42 percent since this time last year.
 
Affymetrix said it will report its quarterly results after market close on Feb. 7.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.